MoneyWorks4Me

Wanbury - Quaterly Results

15 May 2025 Evaluate
The Revenue for the quarter ended  March 2025 of Rs. 1720.00 millions grew by 23.07 % from Rs. 1397.63 millions.The Net Profit of the company vaulted to 150.83% to Rs. 202.57  millions from Rs. 80.76 millions in the previous quarter.Operating profit surged to 314.71 millions from the corresponding previous quarter of 190.88 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1720.00 1397.63 23.07 5995.14 5777.37 3.77 5995.14 5777.37 3.77
Other Income 18.44 5.68 224.65 34.93 9.02 287.25 34.93 9.02 287.25
PBIDT 314.71 190.88 64.87 798.13 729.93 9.34 798.13 729.93 9.34
Interest 90.42 74.60 21.21 369.51 291.81 26.63 369.51 291.81 26.63
PBDT 224.29 116.28 92.89 428.62 438.12 -2.17 428.62 438.12 -2.17
Depreciation 33.74 32.80 2.87 133.11 130.31 2.15 133.11 130.31 2.15
PBT 190.55 83.48 128.26 295.51 307.81 -4.00 295.51 307.81 -4.00
TAX -12.02 2.72 -541.91 -9.79 3.81 -356.96 -9.79 3.81 -356.96
Deferred Tax -70.63 2.72 -2696.69 -68.40 3.81 -1895.28 -68.40 3.81 -1895.28
PAT 202.57 80.76 150.83 305.30 304.00 0.43 305.30 304.00 0.43
Equity 327.71 327.46 0.08 327.71 327.46 0.08 327.71 327.46 0.08
PBIDTM(%) 18.30 13.66 33.97 13.31 12.63 5.37 13.31 12.63 5.37
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..